Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials

BACKGROUND: Regorafenib is a novel multikinase inhibitor (MKI) approved for use in the treatment of metastatic colorectal cancer (CRC), treatment-refractory gastrointestinal stromal tumors, and other solid tumor malignancies. However, the adverse events (AEs) associated with regorafenib have not bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xiaonan, Yin, Yuan, Shen, Chaoyong, Chen, Huijiao, Wang, Jiang, Cai, Zhaolun, Chen, Zhixin, Zhang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174311/
https://www.ncbi.nlm.nih.gov/pubmed/30323618
http://dx.doi.org/10.2147/OTT.S156760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174311/
https://www.ncbi.nlm.nih.gov/pubmed/30323618
http://dx.doi.org/10.2147/OTT.S156760

Ejemplares similares